A majority of hospitals that may be required to participate in the new Medicare cardiac bundled payment models would not experience losses or gains over $500,000 per year, according to a recent analysis by Avalere Health.
A majority of hospitals that may be required to participate in the new Medicare cardiac bundled payment models would not experience losses or gains over $500,000 per year, according to a recent analysis by Avalere Health.
The Centers for Medicare & Medicaid Innovation (CMMI) announced the bundled payment plan for Medicare patients admitted to hospitals for heart attack and cardiac bypass surgery.
The new cardiac bundled payment plan reimburses providers a fixed fee per episode of care, which includes an initial hospital stay and 90 days of care after discharge. Payments are to be based on historical spending levels on a hospital-by-hospital basis; eventually the plan will move toward average regional spending levels. The plan underscores CMS’ commitment to moving Medicare to a value-based environment and away from the fee-for-service model.
Avalere’s analysis finds that some hospitals could face significant penalties because their spending greatly exceeds average regional spending. These high-spending hospitals could be treating sicker patients who don’t have good support systems in place when they are discharged and end up back in the hospital for expensive follow up. Avalere Senior Vice President Josh Seidman noted that many hospitals need to develop a data-analysis infrastructure, cost management discipline, and care coordination capabilities in order to deliver efficient cardiac care.
“We’ve hit a tipping point,” he said, and healthcare executives recognize that CMMI is moving beyond the experimental phase with value-based payment.
CMMI expects to phase in the bundled cardiac payment models starting in July 2017 in 98 randomly selected markets for hospitals that admit Medicare fee-for-service patients who receive 3 types of cardiac care:
Avalere’s analysis found significant differences in the distribution of spending across the 90-day episode between patients who undergo surgical intervention (CABG) and those who do not: 60% to 70% of spending for CABG and PCI episodes occur during the initial hospital stay, whereas only 35% of spending for heart attack patients managed with drugs are connected with the inpatient stay. In the medically managed heart attack patients, 47% of spending is associated with post-discharge care (which includes post-acute services and readmissions to acute care settings).
“There is no magic bullet to achieve savings,” said Fred Bentley, vice president at Avalere. “Participating hospitals will need to pull multiple levers to drive down costs.”
They will need to work even more closely with their physicians to streamline care and promote adherence to clinical guidelines, and accelerate development of high-performance post-acute networks to cut readmissions and achieve efficiencies for medically managed heart attack episodes, he advised.
CMMI is providing hospitals with greater flexibility in the types of arrangements they make with physicians and other provider organizations, so that arrangements allow providers to share in bonuses (as well as penalties) hospitals receive if they can keep spending per episode below the target price (gainsharing). This also allows hospitals to standardize medical devices and negotiate more favorable rates, according to Avalere. Many medical device manufacturers are thus reorienting their business around providing more comprehensive solutions to support more efficient, coordinated care, and are rethinking supply chain and hospital contracting to focus on paying for value over an episode of care.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More